# Clinical Cancer Research

## Contents

| Program Faculty | ................................................................. | 1 |
| Sponsorship and CME Credit | ................................................................. | ii |
| CME Activity Assessment and Evaluation | ................................................................. | iv |

### Novel Agents in the Treatment of Lung Cancer: Fourth Cambridge Conference


---

### Erlotinib: Recent Clinical Results and Ongoing Studies in Non–Small Cell Lung Cancer

Roman Perez-Soler ........................................................................................................ 4589s

---

### HKI-272 in Non–Small Cell Lung Cancer

Kwok-Kin Wong ............................................................................................................. 4593s

---

### Antibodies to the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer: Current Status of Matuzumab and Panitumumab

Mark A. Socinski .......................................................................................................... 4597s

---

### Is There a Role for Cetuximab in Non–Small Cell Lung Cancer?

Daniel Morgensztern and Ramaswamy Govindan ......................................................... 4602s

---

### Selecting Patients for Treatment with Epidermal Growth Factor Tyrosine Kinase Inhibitors

Philip D. Bonomi, Lela Buckingham, and John Coon ..................................................... 4606s

---

### Bevacizumab in Non–Small Cell Lung Cancer

Alan Sandler ................................................................................................................ 4613s

---

### Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors Vandetanib (ZD6474) and AZD2171 in Lung Cancer

Emer O. Hanrahan and John V. Heymach .................................................................... 4617s

---

### Vascular Endothelial Growth Factor Trap in Non–Small Cell Lung Cancer

Gregory J. Riely and Vincent A. Miller ........................................................................ 4623s

---

### Rationale for a Phase I Trial of Erlotinib and the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) for Patients with Relapsed Non–Small Cell Lung Cancer

Bruce E. Johnson, David Jackman, and Pasi A. Jänne .................................................. 4628s

---

### Antagonism of Platelet-Derived Growth Factor Receptor in Non–Small Cell Lung Cancer: Rationale and Investigations

Julie E. Bauman, Keith D. Eaton, and Renato G. Martins ............................................. 4632s

---

### The Role of Phosphoinositide 3-Kinase Pathway Inhibitors in the Treatment of Lung Cancer

Jeffrey A. Engelman ..................................................................................................... 4637s

---

### Enzastaurin, a Protein Kinase Cβ-Selective Inhibitor, and Its Potential Application as an Anticancer Agent in Lung Cancer

Roy S. Herbst, Yun Oh, Asavari Wagle, and Michael Lahn ............................................. 4641s

---

### Incorporating Bortezomib into the Treatment of Lung Cancer

Angela M. Davies, Primo N. Lara, Jr., Philip C. Mack, and David R. Gandara ............... 4647s

---

### L-BLP25: A Peptide Vaccine Strategy in Non–Small Cell Lung Cancer

Randeep Sangha and Charles Butts ............................................................................. 4652s